Aurobindo Pharma's CuraTeQ Ends BioFactura Deal; Shares Flat

• Aurobindo Pharma's unit CuraTeQ terminated its agreement with US-based BioFactura Inc. for biosimilar BFI-751 (Telara/ustekinumab).
• The termination, effective December 27, 2025, was by mutual consent and aligns with CuraTeQ's strategic portfolio prioritisation.
• Aurobindo Pharma clarified the termination will not materially impact its broader biosimilars strategy.
• Separately, Helix Healthcare BV will acquire an additional 20% stake in Luoxin Aurovitas Pharma (Chengdu) Co. Ltd. for $5.125 million, increasing its ownership to 50%.
• Aurobindo Pharma shares traded flat despite the news, having declined 10.8% this year.

Why It Matters: Aurobindo Pharma's unit CuraTeQ ended a biosimilar deal, while another unit expanded a JV; shares flat.